Design Therapeutics (DSGN) Shares Outstanding (Weighted Average) (2020 - 2026)

Design Therapeutics' Shares Outstanding (Weighted Average) history runs 7 years deep, the most recent figure standing at $61.4 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Weighted Average) rose 8.24% year-over-year to $61.4 million; the TTM figure through Mar 2026 stood at $61.4 million (up 8.24% YoY), while the FY2025 annual figure was $57.3 million, up 1.31% from the prior year.
• Shares Outstanding (Weighted Average) came in at $61.4 million for Q1 2026 at Design Therapeutics, up from $57.3 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $61.4 million in Q1 2026 to a low of $55.5 million in Q1 2022.
• A 5-year average of $56.6 million and a median of $56.5 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
• Across the five-year window, Shares Outstanding (Weighted Average) surged 214.84% in 2022 and rose 0.48% in 2025, its largest moves.
• Design Therapeutics' Shares Outstanding (Weighted Average) stood at $55.7 million in 2022, then grew by 0.5% to $56.0 million in 2023, then rose by 1.08% to $56.6 million in 2024, then rose by 1.31% to $57.3 million in 2025, then climbed by 7.16% to $61.4 million in 2026.
• According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods registered $61.4 million, $57.3 million, and $57.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison